

STATE: MINNESOTA
Effective: January 19, 2010
TN: 10-01
Approved: **APR 21 2010**
Supersedes: 08-13 (07-12,07-04,05-09/04-15(a)/03-29)

ATTACHMENT 4.19-B
Page 37a

12a. Prescribed Drugs (continued);

For drugs administered in an outpatient setting, payment for prescription drugs is the lower of the provider's usual and customary charge to the general public or the amount established for Medicare Part B.

Effective July 1, 2005, for antihemophilic factor drugs, the State agency establishes the actual acquisition cost to equal 70% of the average wholesale price (wholesale price minus 30%).

Effective March 1, 2007, the rate for specialty pharmacy products is 84.5% or 83% of average wholesale price. The rate used is dependent upon the actual acquisition cost for the product. Specialty pharmacy products are those used by a small number of recipients or recipients with complex and chronic diseases that require expensive and challenging drug regimens.

Following is the chart listing either the class of the categories of specialty pharmacy products that receive one of the two discounts from the average wholesale price or the actual specialty pharmacy product that receives one of the two discounts from the average wholesale price. Further detail can be found in the Minnesota Health Care Program Provider Manual available through the agency's website..

STATE: MINNESOTA
 Effective: January 19, 2010
 TN: 10-01

ATTACHMENT 4.19-B
 Page 37b

Approved: APR 21 2010
 Supersedes: 08-13 (07-12, 07-04, 05-09/04-15(a)/03-29)

12a. Prescribed Drugs (continued):

Drug name or class	% discount from AWP
Drugs for Multiple Sclerosis	15.5%
Disease Modifying AntiRheumatic Drugs	15.5%
Hepatic C	15.5%
Anemia, Neutropenia, Thrombocytopenia	15.5%
Enzyme Replacement	15.5%
Immune Globulin	15.5%
HIV Antivirals	15.5%
Growth Hormone	15.5%
Oral Chemotherapy and Oral Pulmonary Hypertension	17%
Leuprolide acetate	15.5%
Octreotide	15.5%
Actimmune	15.5%
Aldurazyme	15.5%
Apokyn	15.5%
Baraclude	15.5%
Forteo	15.5%
Fuzeon	15.5%
Hyalgan	15.5%
Remodulin	15.5%
Risperdal consta	15.5%
Rituxan	15.5%
Sensipar	15.5%
Synvisc	15.5%
Temodar	15.5%
Thyrogen	15.5%
Tobi	17%
Ventavis	15.5%
Xeloda	15.5%
Xolair	15.5%
Zavesca	15.5%
Zoladex	15.5%

Drug Name or Therapeutic Area	% discount from AWP
Biologic Agents	15.5%
Immunologic Agents	15.5%
Endocrine and Metabolic Agents	15.5%
Enzyme Replacement Agents	15.5%
Injectable Antipsychotic Agents	15.5%
Pulmonary Hypertension Agents	15.5%
Oral Neoplastic Agents	17%